spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  follicular lymphoma 

 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 16 Dec 2021
Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jun 2018
Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Oct 2016
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biopharmaceuticals Oncology Personalized Medicine
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2006
New Landmark Study Shows the Use of a BiovaxID Formulation Improves Disease Free survival in 80% of Patients Whose Cancer has Relapsed after Chemotherapy Administered With or Without Rituxan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2006
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at Over Nine Years Follow-Up To Be Presented
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
follicular lymphoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.